Related Experiment Video

Updated: Sep 8, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma

Qilong Su1, Jingyu Hou1, Xinhui Du1

  • 1The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Oncology Reviews
|July 2, 2025
PubMed

Insights

MET (mesenchymal-epithelial transition) receptor tyrosine kinase signaling drives osteosarcoma (OS) progression. MET-targeted therapies, including combination treatments, show promise for improving patient outcomes in OS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MET, a receptor tyrosine kinase, is crucial in osteosarcoma (OS) initiation and progression.
  • Sustained MET pathway activation drives OS cell proliferation, invasion, differentiation, and drug resistance via downstream signaling (RAS-ERK, PI3K-AKT, STAT3).

Purpose of the Study:

  • To review the mechanisms of MET signaling in osteosarcoma.
  • To summarize the advancements in MET-targeted therapies and combination strategies for OS treatment.

Main Methods:

  • Literature review focusing on MET signaling pathways in osteosarcoma.
  • Analysis of current and emerging MET-targeted therapeutic approaches.
  • Evaluation of combination therapy strategies involving MET inhibitors.

Main Results:

  • MET signaling is a key driver of osteosarcoma development and progression.
  • Small-molecule inhibitors and antibodies targeting MET are advancing for OS therapy.
  • Combination therapies (MET inhibitors with chemotherapy, immunotherapy, or other targeted agents) demonstrate potential to overcome resistance and enhance efficacy.

Conclusions:

  • MET is a significant therapeutic target in osteosarcoma.
  • Targeting MET, particularly through combination therapies, offers a promising strategy to improve treatment outcomes for osteosarcoma patients.
  • Further research into MET-targeted therapies and their combinations is warranted for novel perspectives in OS treatment.
Keywords:
MET signalling pathwaycombination therapyosteosarcomasmall molecule inhibitorsspecific antibodytargeted therapy

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.4K